期刊文献+

原发性胆汁性肝硬化无创性肝纤维化诊断模型的验证 被引量:3

The noninvasive diagnostic models for primary biliary cirrhosis
下载PDF
导出
摘要 目的验证采用常规实验室指标建立的无创性肝纤维化诊断模型,并评判其对原发性胆汁性肝硬化(PBC)患者组织学分期的诊断价值。方法采用受试者工作特征曲线下面积(AUC)检测各项无创诊断模型对PBC患者组织学分期的诊断价值。结果各项模型均对PBC的组织学分期有一定诊断价值,其中H指数、Forns评分及RPR预测价值最为突出,AUC分别可达0.851,0.811和0.843。结论由常规实验室指标建立的肝纤维化无创诊断模型H指数、Forns评分及RPR能协助准确区分PBC患者的早期(Ⅰ-Ⅱ期)和进展期(Ⅲ-Ⅳ期)病变。 Objective To verify the noninvasive diagnostic models of liver fibrosis in primary biliary cirrhosis(PBC),and to assess its diagnostic value on histologic staging.Methods Diagnostic value of the models on histologic staging was assessed by the receiver operating characteristic curve(AUC).Results The noninvasive diagnostic models had different levels of diagnostic values,especially H index,Forns Score and RPR,which could predict advanced fibrosis(stage III-IV)with an area under the receiver operating characteristic curve(AUROC)of 0.851,0.811 and 0.843,respectively.Conclusion The noninvasive models of H index,Forns Score and RPR,which were consisting of laboratory markers,could help accurately identify early(stage I-II)and advanced(stage III-IV)liver fibrosis in patients with PBC.
出处 《肝脏》 2016年第2期105-106,134,共3页 Chinese Hepatology
关键词 原发性胆汁性肝硬化 无创诊断模型 肝纤维化 Primary biliary cirrhosis Noninvasive diagnostic model Liver fibrosis
  • 相关文献

参考文献12

  • 1Martinez SM, Crespo G, Navasa M, et al. Noninvasive assessment of liver fibrosis. Hepatology, 2011, 53. 325-335.
  • 2马佳丽,王蕊,张福奎,贾继东,欧晓娟,张涛,王宇,段维佳,赵新颜,尤红,马红.原发性胆汁性肝硬化无创性肝纤维化诊断模型的建立[J].中华内科杂志,2012,51(8):618-622. 被引量:3
  • 3Su CW, Chan CC, Hung HH, et al. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterul, 2009, 43:876 -883.
  • 4Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 2002, 36: 986-992.
  • 5Wai CH, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patient with chronic hepatitis C. Hepatology, 2003, 38: 518 -526.
  • 6Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology, 2005, 42: 282-292.
  • 7Taefi A, Huang CC, Kolli K, et al. Red cell distribution width to platlet ratio, a useful indicater of liver fibrosis in chronic hepatitis patients. Hepatol Int, 2015, 9:454-460.
  • 8Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology, 2009, 50: 291-308.
  • 9Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patient with HIV/HCV coinfection. Hepat61ogy, 2006, 43:1317 -1325.
  • 10Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4.- an inexpensive and accurate marker of fibrosis in HCV infection, comparison with liver biopsy and fibrotest. Hepatology, 2007, 46: 32-36.

二级参考文献17

  • 1Martínez SM, Crespo G, Navasa M, et al.Noninvasive assessment of liver fibrosis.Hepatology,2011,53:325-335.
  • 2Imbert-Bismut F, Ratziu V, Pieroni L, et al.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet,2001,357:1069-1075.
  • 3Rosenberg WM, Voelker M, Thiel R, et al.Serum markers detect the presence of liver fibrosis: a cohort study.Gastroenterology,2004,127:1704-1713.
  • 4Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.BMC Gastroenterol, 2010,10:103.
  • 5Su CW, Chan CC, Hung HH, et al.Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis.J Clin Gastroenterol,2009,43:876-883.
  • 6Corpechot C, Poujol-Robert A, Wendum D, et al.Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.Liver Int,2004,24:187-193.
  • 7Frkkil M, Rautiainen H, Krkkinen P, et al.Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.Liver Int,2008,28:787-797.
  • 8Lindor KD, Gershwin ME, Poupon R, et al.Primary biliary cirrhosis.Hepatology, 2009,50:291-308.
  • 9Forns X, Ampurdanès S, Llovet JM, et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.Hepatology,2002,36(4 Pt 1):986-992.
  • 10Wai CT, Greenson JK, Fontana RJ,et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Hepatology,2003,38:518-526.

共引文献2

同被引文献33

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部